ArticleCurrent microbiology2011
P-27/HP endolysin as antibacterial agent for antibiotic resistant Staphylococcus aureus of human infections.
Article in Current microbiology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 37 citations in OpenAlex.
- PlyNJ3: a three-domain endolysin with broad-spectrum anti-streptococcal activity and synergistic efficacy against multidrug-resistant Streptococcus suis.BMC veterinary research · 2025Article
- Phage-Derived Endolysins Against Resistant Staphylococcus spp.: A Review of Features, Antibacterial Activities, and Recent Applications.Infectious diseases and therapy · 2025Review
- Treating Bacterial Infections with Bacteriophage-Based Enzybiotics: In Vitro, In Vivo and Clinical Application.Antibiotics (Basel, Switzerland) · 2021Review
- Characterization of staphylococcal endolysin LysSAP33 possessing untypical domain composition.Journal of microbiology (Seoul, Korea) · 2021Article
- Exploring Codon Adjustment Strategies towardsViruses · 2021Article
- Intrinsic resistance of Enterococcus faecalis strains to ΦEf11 phage endolysin is associated with the presence of ΦEf11 prophage.Archives of virology · 2021Article
- Article
- Biological challenges of phage therapy and proposed solutions: a literature review.Expert review of anti-infective therapy · 2019Review
- Bacteriophage φEf11 ORF28 Endolysin, a Multifunctional Lytic Enzyme with Properties Distinct from All Other Identified Enterococcus faecalis Phage Endolysins.Applied and environmental microbiology · 2019Article
- Applications of bacteriophages versus phage enzymes to combat and cure bacterial infections: an ambitious and also a realistic application?Applied microbiology and biotechnology · 2018Review
- Review
- Vascular Graft Impregnation with Antibiotics: The Influence of High Concentrations of Rifampin, Vancomycin, Daptomycin, and Bacteriophage Endolysin HY-133 on Viability of Vascular Cells.Medical science monitor basic research · 2017Article
- Wall Teichoic Acids Are Involved in the Medium-Induced Loss of Function of the Autolysin CD11 against Clostridium difficile.Scientific reports · 2016Article
- Bacteriophages and phage-derived proteins--application approaches.Current medicinal chemistry · 2015Review
- Review
- Mitrecin A, an endolysin-like bacteriolytic enzyme from a newly isolated soil streptomycete.Letters in applied microbiology · 2014Article
- Expression and delivery of an endolysin to combat Clostridium perfringens.Applied microbiology and biotechnology · 2014Article
- Characteristics of a broad lytic spectrum endolysin from phage BtCS33 of Bacillus thuringiensis.BMC microbiology · 2012Article
- Learning from bacteriophages - advantages and limitations of phage and phage-encoded protein applications.Current protein & peptide science · 2012Review
- Peptidoglycan hydrolases-potential weapons against Staphylococcus aureus.Applied microbiology and biotechnology · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Staphylococcus aureus causes a wide range of suppurative infections in humans and animals. Due to its high virulence, ability to adopt various environmental conditions, and acquired multiple drug resistance, treatment of such infections has become difficult. Therefore, there is an immense need to develop alternate drug modalities to control this pathogen. In past few years, phage-encoded endolysin therapy has emerged as a new hope not only due to its ability to specifically kill the target bacteria irrespective of their antibiotic sensitivity but also because of minimum or no side effects, a problem associated with antibiotic therapy. In this article, we report purification of a broad spectrum anti-staphylococcal endolysin (P-27/HP endolysin) encoded by phage P-27/HP isolated from sewage water. On SDS-PAGE endolysin resolved in three polypeptides of molecular weights 33.5, 48.6, and 62.2 kDa. Endolysin exhibited maximum in vitro lytic activity at temperature between 35 and 40°C and pH 7.0. In vivo experiments revealed considerable (99.9%) elimination of S. aureus 27/HP from spleens of endolysin-treated mice and had saved them from death due to bacteremia caused by S. aureus 27/HP challenge infection. Thus, P-27/HP endolysin offers suitable substitute of antibiotics to control S. aureus infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.